drugset / Trial / NCT01327651

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

NCT01327651

Phase 2 Completed 622 enrolled HIV Prevention Trials Network
RandomizedParallel-groupOpen-labelPrevention

Summary

Pre-exposure prophylaxis (PrEP) is a method of preventing HIV infection through the use of antiretroviral (ARV) medications before exposure to HIV. This study will examine the feasibility of different methods of dosing for a PrEP regimen. Three methods of delivery will be compared: daily, time-based, and event-based.

Timeline

Start
2011-08
Primary completion
2014-12
Completion
2014-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule Oral
Subject emtricitabine Other / unclassified Oral